Endoscopic sleeve gastroplasty reshapes the stomach with sutures placed through the mouth, without incisions, and produces middle-ground weight loss: less than bariatric surgery, more than most balloons. Intragastric balloons are temporary devices producing smaller and largely temporary loss. Both are less invasive and less powerful than surgery, and both depend on lasting lifestyle change to hold a result.
Where endoscopic treatments sit
Endoscopic bariatric therapies occupy the gap between medication and surgery. They are performed through a flexible scope passed through the mouth — no incisions, no rerouting of the bowel, usually as an outpatient — which makes them less invasive than an operation and also less powerful than one. Some are temporary by design. Two categories matter in practice: endoscopic sleeve gastroplasty (ESG) and intragastric balloons. → The WeightExperts Clinical Approach
Endoscopic sleeve gastroplasty (ESG)
An endoscopist places a series of sutures inside the stomach to fold and shrink it into a tube-like shape, reducing volume and slowing emptying. No part of the stomach is removed and nothing is rerouted. It is often called an incisionless sleeve, but it is not the same procedure as a surgical sleeve gastrectomy.
- Weight loss: middle-ground — less than surgical sleeve gastrectomy or bypass, more than most balloons. A randomised trial, MERIT, supports meaningful weight loss against lifestyle alone.
- Invasiveness: no incisions, typically outpatient, with faster recovery than surgery.
- Reversibility: no organ is removed, but the procedure is not simply undone; it is semi-durable rather than easily reversible.
- Durability: better than a balloon. Sutures can loosen over time, and the result still rests on sustained behaviour change.
- Risks: generally lower than surgery — bleeding, pain and nausea. Serious complications, including leak, collection and bleeding requiring intervention, are uncommon but possible.
ESG is the more substantial of the two endoscopic options and the closer analogue to surgery, at lower efficacy and lower risk. Grade B 🟡
Intragastric balloons
A soft balloon is placed in the stomach, endoscopically or in some cases swallowed as a capsule, then filled with saline or gas so that it occupies space and promotes fullness. It is temporary: most are removed after about 6 months.
- Weight loss: smaller than with ESG, and largely temporary. A substantial portion is commonly regained after removal unless lifestyle change is sustained.
- Invasiveness: minimal, often with no incision and, for swallowable types, sometimes no sedation.
- Reversibility: complete by design, since the device comes out.
- Durability: the central limitation. The balloon creates a window, and whether loss persists depends on what happens during and after it.
- Risks: nausea and vomiting are very common early. Less commonly, ulceration and balloon deflation or migration; rarely, obstruction or perforation. Regulators have noted rare serious events, so device selection and monitoring matter.
A balloon functions as a temporary window rather than a standalone treatment. Grade B 🟡 / C 🟠 (durability limited).
Effect sizes in rank order
Stated as procedure averages rather than single headline numbers, the effects rank consistently: bariatric surgery (~25–30% total) > ESG > intragastric balloon > lifestyle alone.
Against medication the comparison is now close. Potent GLP-1/GIP drugs — tirzepatide at ~15–20.9% treatment-policy in SURMOUNT-1, semaglutide at ~15% in STEP 1 — produce weight loss that overlaps with or exceeds ESG, with no procedure at all. Every figure here is an average that varies between people, and every endoscopic result depends on sustained lifestyle change. Grade B 🟡 → Semaglutide · Tirzepatide
Durability
Durability is the feature that separates the two procedures. Balloon weight loss is largely temporary, and regain after removal is common without sustained behaviour change. ESG holds better than a balloon but less well than surgery, since sutures can loosen and long-term maintenance still rests on lifestyle. Neither procedure overrides the body's tendency to defend its weight, so the window either one creates is worth what the maintenance plan built around it is worth — which is why that plan is made before the procedure rather than after. → Weight Regain & Maintenance
Against surgery, and against medication
Endoscopic procedures, ESG in particular, produce meaningful but smaller weight loss than surgery, with lower invasiveness and lower complication risk. Surgery produces the largest average loss, ~25–30%, and holds the strongest diabetes-remission and long-term outcome data. What remains unknown is the long-term durability of ESG against surgery across many years, the comparative metabolic and diabetes outcomes, and the best way to combine endoscopic therapy with medication.
In our practice, endoscopic therapy is a reasonable middle option for patients who want something less invasive than surgery, who do not qualify for or do not want an operation, or who need a bridge — chosen in the knowledge that it is less powerful and, for balloons, largely temporary, and that it does not carry surgery's diabetes-remission or mortality evidence. Grade B 🟡
The comparison with medication has moved fastest. Potent GLP-1/GIP drugs now overlap ESG and exceed balloons without a procedure or sedation, and semaglutide carries a cardiovascular-outcome benefit — SELECT, with a ~20% reduction in major adverse cardiovascular events — for which endoscopic therapy has no equivalent. Medication, though, generally requires ongoing use, and stopping usually brings regain: the STEP 1 extension recorded roughly two-thirds of lost weight regained within about a year. An endoscopic procedure is instead a discrete intervention. The two can also be combined, with a procedure plus medication, or medication after a balloon, both legitimate strategies, so procedure-or-drug is rarely a clean either/or. Grade B 🟡 → GLP-1 & Incretin Medications
Candidacy, and the limits of these procedures
Reasonable candidates often include people with obesity who do not qualify for or do not want bariatric surgery, who want a less invasive and reversible or semi-durable option, or who need a bridge — for example to reduce surgical risk before another procedure — and who accept that the effect is smaller than surgery's and, for balloons, largely temporary. Candidacy is a clinical question grounded in a person's health and goals rather than BMI alone. → How Obesity Should Be Evaluated · BMI, Body Fat & Body Composition
The limits are worth stating as plainly as the benefits. These procedures do not match surgery's weight loss or its diabetes-remission and mortality evidence. Balloons do not produce lasting loss on their own. Neither removes the need for lifestyle change, since sustained behaviour is what holds any result, and neither alters the biology of weight regain. → Weight Regain & Maintenance
What the evidence says: endoscopic obesity treatment
- What we know: ESG produces meaningful, middle-ground weight loss with low invasiveness; balloons produce smaller, largely temporary loss. Both are safer and weaker than surgery. Grade B 🟡
- What we think: in our hands endoscopic therapy is a genuine option for the right patient, more substantial than lifestyle alone and less invasive than surgery, with its value resting on the maintenance plan and, increasingly, on how it is combined with medication.
- What we don't know: the long-term durability of ESG against surgery, comparative metabolic outcomes, and the optimal role alongside GLP-1 drugs.
- What follows clinically: an endoscopic procedure is matched to goals and preferences, chosen in the knowledge that it is less powerful than surgery and, for balloons, temporary, with maintenance planned before it starts.
Whether either procedure fits a particular person, and how it would sit alongside medication, is the subject of an individual assessment at the practice.
Questions patients ask
What is endoscopic sleeve gastroplasty?
A procedure in which an endoscopist places sutures inside the stomach through the mouth to fold and shrink it. There are no incisions, no organ is removed and nothing is rerouted. It is often called an incisionless sleeve, but it is not the same as a surgical sleeve gastrectomy. Grade B 🟡
How much weight does ESG produce?
Middle-ground: less than a surgical sleeve or bypass, more than most balloons. The randomised MERIT trial supports meaningful loss against lifestyle alone. The figure is an average that varies between people and depends heavily on sustained lifestyle change. Grade B 🟡 → Bariatric Surgery
What is a gastric balloon, and how long does it stay in?
A soft balloon placed in the stomach and filled to promote fullness. Most are temporary and removed after about 6 months. Grade B 🟡
Does the weight stay off after a balloon is removed?
Often not fully. Balloon weight loss is largely temporary, and a substantial portion is commonly regained unless lifestyle change is sustained. Grade C 🟠 → Weight Regain & Maintenance
Is ESG reversible?
No organ is removed, but it is not simply undone, and it is better described as semi-durable than as reversible. A balloon, by contrast, is fully reversible by removal. Grade B 🟡
Is sedation or anesthesia needed?
ESG and endoscopically placed balloons are typically done under sedation as outpatient procedures. Some swallowable balloons need little or no sedation. Grade B 🟡
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: ASGE/ASMBS guidance on endoscopic bariatric therapies; randomised and prospective data on endoscopic sleeve gastroplasty (e.g. MERIT) and intragastric balloons; SURMOUNT and STEP programs for medication comparison. Effect sizes stated qualitatively where exact figures require re-verification. Educational only; not individualized medical advice.
